RespireRx Pharmaceuticals Inc (RSPI)

[ombowstring]

I e-mailed D. Stoll as follows:

Dr. Stoll,



How about conducting a 2 week AD trial with CX717 using the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) on real people to see what kind of results we get?



With all the clinical studies and research papers that have been done on AMPAKINES, it seems that some Big Pharma ought to be interested in a long-term partnership deal similar to the collaboration agreement that EPIX has with GSK with a potential value of $1.2 billion to EPIX whereby Cortex could continue doing basically what it is doing and the BP has options to license various AMPAKINES for various indications based on how the various compounds perform in treating various CNS and other indications.



Sincerely,

John Mackenzie